Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Daflorn is a Bulgarian biotechnology and consumer health company focused on probiotic foods and dietary supplements. The company develops and markets branded probiotic products, particularly under the Laktera label, using proprietary wild strains of Lactobacillus bulgaricus and other lactic acid bacteria isolated from Bulgarian spring water. Daflorn emphasizes patented strain discovery, in-house raw material production, fermentation, and freeze-drying to create shelf-stable probiotic formulations. Its portfolio appears to be commercially marketed rather than a traditional prescription-drug pipeline, with products positioned for digestive health, immune support, and broader wellness applications. The business sits at the intersection of biotech, nutraceuticals, and microbiome-focused consumer health.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Daflorn.